AI Article Synopsis
- * Recent advancements have uncovered several targetable genetic changes in SGC, such as HER2, androgen receptors, and NTRK fusions, leading to better treatment outcomes.
- * The review discusses the current state of precision therapy for SGC, including existing treatment options, ongoing clinical trials, and future prospects for improving patient care.
Article Abstract
Salivary gland carcinomas (SGC) are a rare and variable group of head and neck cancers with historically poor response to cytotoxic chemotherapy and immunotherapy in the recurrent, advanced, and metastatic settings. In the last decade, a number of targetable molecular alterations have been identified in SGCs including HER2 upregulation, androgen receptor overexpression, Notch receptor activation, NTRK gene fusions, and RET alterations which have dramatically improved treatment outcomes in this disease. Here, we review the landscape of precision therapy in SGC including current options for systemic management, ongoing clinical trials, and promising future directions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.27307 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!